A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) in Patients With Malignant Pleural Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Erlotinib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Mar 2008 Status changed from completed to in progress, as reported by ClinicalTrials.gov.